Key facts
- This page summarizes Alexander Nolte's Form 4 filing for Syndax Pharmaceuticals Inc (SNDX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 Feb 2023, 15:58.
Alexander Nolte - 02 Feb 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)
- Reporting relationship
- Chief Accounting Officer
- Issuer ticker
- SNDX
- Reported as of
- 02 Feb 2023
- Net transaction value
- +$485,350
- SEC form
- 4
- Accepted by SEC
- 03 Feb 2023, 15:58:24 UTC
- Prior SEC filing
- 03 Feb 2022
- Next SEC filing
- 22 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael A. Metzger, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alexander Nolte filed Form 4 for Syndax Pharmaceuticals Inc (SNDX) on 03 Feb 2023.
Change
- Previous filing in this sequence was filed on 03 Feb 2022.
- Current net transaction value: +$485,350.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SNDX
transaction
Derivative
Stock Options (Right to buy)
Award
- Transaction value
- $485,350
- Shares
- +17,000
- Change %
- Price
- $28.55
- Shares after
- 17,000
- Date
- 02 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,000
- Exercise price
- $28.55
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
1/48th of the shares subject to the option shall vest monthly over a four-year period.